INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,999 | -78.0% | 1,672 | -86.8% | 0.00% | -80.0% |
| Q2 2023 | $140,595 | +104821.6% | 12,712 | +27.5% | 0.01% | +25.0% |
| Q1 2023 | $134 | +9.8% | 9,973 | +1.0% | 0.00% | -20.0% |
| Q4 2022 | $122 | -100.0% | 9,876 | -73.6% | 0.01% | -37.5% |
| Q3 2022 | $521,000 | +349.1% | 37,372 | +343.9% | 0.01% | +166.7% |
| Q2 2022 | $116,000 | +81.2% | 8,419 | +112.5% | 0.00% | +200.0% |
| Q1 2022 | $64,000 | -48.0% | 3,962 | -47.4% | 0.00% | -50.0% |
| Q4 2021 | $123,000 | -48.5% | 7,538 | -53.1% | 0.00% | -66.7% |
| Q3 2021 | $239,000 | +342.6% | 16,073 | +492.7% | 0.01% | +500.0% |
| Q2 2021 | $54,000 | +3.8% | 2,712 | +20.5% | 0.00% | 0.0% |
| Q1 2021 | $52,000 | -78.5% | 2,251 | -77.1% | 0.00% | -85.7% |
| Q4 2020 | $242,000 | +188.1% | 9,812 | +386.2% | 0.01% | +600.0% |
| Q3 2020 | $84,000 | -55.6% | 2,018 | -49.0% | 0.00% | -87.5% |
| Q2 2020 | $189,000 | +425.0% | 3,956 | +619.3% | 0.01% | +300.0% |
| Q3 2019 | $36,000 | +100.0% | 550 | +239.5% | 0.00% | +100.0% |
| Q1 2019 | $18,000 | -30.8% | 162 | -37.5% | 0.00% | -50.0% |
| Q4 2018 | $26,000 | +100.0% | 259 | +161.6% | 0.00% | +100.0% |
| Q3 2018 | $13,000 | -89.0% | 99 | -94.8% | 0.00% | -90.0% |
| Q1 2018 | $118,000 | +93.4% | 1,916 | +84.9% | 0.01% | +25.0% |
| Q4 2017 | $61,000 | +35.6% | 1,036 | +33.2% | 0.01% | +100.0% |
| Q3 2017 | $45,000 | +200.0% | 778 | +507.8% | 0.00% | +100.0% |
| Q2 2017 | $15,000 | +200.0% | 128 | +204.8% | 0.00% | – |
| Q1 2017 | $5,000 | -78.3% | 42 | -80.1% | 0.00% | -100.0% |
| Q4 2016 | $23,000 | +155.6% | 211 | +276.8% | 0.00% | +100.0% |
| Q3 2016 | $9,000 | -55.0% | 56 | -60.3% | 0.00% | -50.0% |
| Q2 2016 | $20,000 | -81.7% | 141 | -83.3% | 0.00% | -87.5% |
| Q1 2016 | $109,000 | +738.5% | 846 | +1526.9% | 0.02% | +1500.0% |
| Q2 2015 | $13,000 | +550.0% | 52 | +642.9% | 0.00% | – |
| Q3 2014 | $2,000 | -97.4% | 7 | -99.4% | 0.00% | -100.0% |
| Q4 2013 | $78,000 | +212.0% | 1,146 | +217.5% | 0.01% | +333.3% |
| Q3 2013 | $25,000 | +8.7% | 361 | -30.8% | 0.00% | +50.0% |
| Q2 2013 | $23,000 | – | 522 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |